Journey Medical Corporation (DERM)
DERM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DERM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001867066 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $61.9M |
| Net income | -$11.4M |
| Operating income | -$8.2M |
| Net margin | -18.5% |
| Operating margin | -13.2% |
| Revenue growth | +10.2% |
| Cash | $24.1M |
| Total assets | $94.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements." | 10-Q 2026-11-12 |
| Cash and burn | $22.3M cash; operating cash flow -$2.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 28,230,645 (2026-11-12); 27,135,905 a year earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-01-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.0M | -$1.3M | -$3.4M | $22.3M | $25.6M | $69.5M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $18.5M | -$312K | -$1.7M | $25.6M | $25.5M | $68.2M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $16.0M | -$2.2M | $2.9M | $27.2M | $25.4M | $64.7M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $16.1M | -$1.2M | -$6.3M | $24.1M | $25.3M | $61.9M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $17.6M | -$2.3M | -$2.4M | $24.9M | $25.2M | $59.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $15.0M | -$3.8M | -$942K | $20.3M | $25.1M | $56.4M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $13.1M | -$4.1M | -$2.8M | $21.1M | $25.0M | $56.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $13.6M | $1.5M | $2.2M | $20.3M | $24.9M | $56.1M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-01-23 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 231 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.1% |
| 1 month | -23.8% |
| 3 months | -34.9% |
| Year to date | -43.8% |
| 1 year | -43.7% |
| From 52-week high | -53.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier